Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 15, Issue 1, 2000, Pages 34-42

  Syrjänen, Jaana ^a,b   Mustonen, Jukka ^a   Pasternack, Amos ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Glomerulonephritis; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia; IgA nephropathy; Uric acid

Indexed keywords

CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URATE;

ADULT; AGED; ARTICLE; BODY MASS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHOOL CHILD; SMOKING HABIT; URIC ACID BLOOD LEVEL;

EID: 17344389079     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.1.34     Document Type: Article

References (53)

1. French JW, Yamanaka BS, Ostwald R. Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol 1967, 83: 204-220
2. Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol. Kidney Int 1987; 32: 671-677
3. Kasiske BL, O'Donnell NIP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-672
4. Kasiske BL, O'Donnell MP, Cowardin W, Keane WK. Lipids and the kidney. Hypertension 1990; 15: 443-450
5. Harris KPG, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15: 16-23
6. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis, a model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
7. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney lnt 1991; 39: S29-34
8. Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910-920
9. Attman P-O, Samuelsson O, Alaupovic P. Progression of renal failure: Role of apolipoprotein B-containing lipoproteins. Kidney Int 1997; 42: S98-101
10. Gjone E. Familial lecithin: cholesterol acyltransferase deficiency - a new metabolic disease with renal involvement. Adv Nephrol 1981; 10: 167-185
11. Saito T, Sato H, Oikawa S et al. Lipoprotein glomerulopathy: Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13: 64-68
12. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26: 670-675
13. Attman P-O, Samuelsson O, Alaupovic P. Lipid metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
14. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311
15. Mulec H, Johnsen SA, Wiklund O, Björck S. Cholesterol: A renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993; 22: 196-201
16. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994; 45: S125-131
17. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-609
18. Samuelsson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915
19. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomeruloscierosis in children. Pediatr Nephrol 1991; 5: 393-397
20. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricaemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464
21. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid: a facet of hyperinsulinemia. Diabetologia 1987; 30: 713-718
22. Persky VW, Dyer AR, Idris-Soven E et al. Uric acid: a risk factor for coronary heart disease. Circulation 1979; 59: 969-977
23. Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-639
24. D'Amico G. The commonest glomcrulonephritis in the world: IgA nephropathy. Q J Med 1987; 245: 709-727
25. Packham D. Prognosis in IgA nephropathy. Nephrology 1997; 3: 231-235
26. D'Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993; 104: 6-13
27. Mustonen J, Pasternack A, Helin H, Nikkilä M. Clinico-pathologic correlations in a series of 143 patients with IgA glomerulonephritis. Am J Nephrol 1985; 5: 150-157
28. Mustonen J, Pasternack A. Associated diseases in IgA nephropathy. In: Clarkson AR, ed. IgA Nephropathy. Martinus Nijhoff, Boston: 1987: 47-65
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotcin cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972; 18: 499-502
30. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks, odds ratios, and standardised ratios and rates. In: Gardner MJ, Altman DG, ed. Statistics With Confidence. Confidence Intervals and Statistical Guidelines. British Medical Journal, London, 1992; 50-63
31. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall, London, 1984
32. Alamartine E, Sabatier J-C, Guerin C, Berliet J-M, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18: 12-19
33. Bagdade JD, Porte DJ, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181-185
34. Huttunen JK, Pasternack A, Vänttinen T, Ehnholm C, Nikkilä EA. Lipoprotein metabolism in patients with chronic uremia. Acta Med Scand 1978; 204: 211-218
35. Maschio G, Oldrizzi L, Rugiu C, De Biase V, Loschiavo C. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney Int 1991; 39: S70-72
36. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P. Attman P-O. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285
37. Feiner HD, Cabili S, Baldwin DS, Schacht RG, Gallo GR. Intrarenal vascular sclerosis in IgA nephropathy. Clin Nephrol 1982; 18: 183-192
38. D'Amico G, Imbasciati E, Barbiano de Belgioioso G et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 1985; 64: 49-60
39. Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990; 34: 45-51
40. Steinberg D, Witztum JL. Lipoproteins and atherosclerosis. Current concepts. JAMA 1990; 264: 3047-3052
41. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219
42. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-1036
43. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998; 141 [Suppl. 1]: S57-62
44. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11-18
45. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988; 41: 237-242
46. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821
47. Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986; 146: 272-276
48. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease [Editorial]. Am J Kidney Dis 1999; 33: 225-234
49. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
50. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011
51. Eliasson B, Mero N, Taskinen MR, Smith U. The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis 1997; 129: 79-88
52. Fliser D, Pacini G, Engelleiteir R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347
53. Reaven GM. The kidney: an unwilling accomplice in Syndrome X. Am J Kidney Dis 1997; 30: 928-931